133 related articles for article (PubMed ID: 7840601)
21. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
Credito KL; Ednie LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2027-31. PubMed ID: 10428930
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial susceptibilities of anaerobic bacteria: recent clinical isolates.
Staneck JL; Washington JA
Antimicrob Agents Chemother; 1974 Sep; 6(3):311-5. PubMed ID: 15830478
[TBL] [Abstract][Full Text] [Related]
23. The in-vitro activity of doxycycline and minocycline against anaerobic bacteria.
Robbins M; Marais R; Felmingham D; Ridgway GL
J Antimicrob Chemother; 1987 Sep; 20(3):379-82. PubMed ID: 3680075
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species.
Goldstein EJC; Citron DM; Tyrrell KL
Anaerobe; 2018 Aug; 52():122-124. PubMed ID: 30018028
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility testing of 7 antibiotics against anaerobic bacteria: comparison of 2 different media and carbon dioxide concentrations.
Jansen JE; Bremmelgaard A
Acta Pathol Microbiol Immunol Scand B; 1987 Feb; 95(1):65-73. PubMed ID: 3105247
[TBL] [Abstract][Full Text] [Related]
26. Development of resistance to metronidazole and minocycline in vitro.
Larsen T; Fiehn NE
J Clin Periodontol; 1997 Apr; 24(4):254-9. PubMed ID: 9144048
[TBL] [Abstract][Full Text] [Related]
27. Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Nov; 38(11):2599-604. PubMed ID: 7872754
[TBL] [Abstract][Full Text] [Related]
28. Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole.
Credito KL; Jacobs MR; Appelbaum PC
Diagn Microbiol Infect Dis; 2000 Nov; 38(3):181-3. PubMed ID: 11109019
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility of anaerobic bacteria to 23 antimicrobial agents.
Sutter VL; Finegold SM
Antimicrob Agents Chemother; 1976 Oct; 10(4):736-52. PubMed ID: 984809
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of tigecycline and comparators against a European collection of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2010-2016.
Rodloff AC; Dowzicky MJ
Anaerobe; 2018 Jun; 51():78-88. PubMed ID: 29679648
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial resistance and resistance transfer in anaerobic. A review.
Tally FP; Malamy MH
Scand J Gastroenterol Suppl; 1984; 91():21-30. PubMed ID: 6377471
[TBL] [Abstract][Full Text] [Related]
32. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
33. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species.
Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2006 Mar; 50(3):1112-7. PubMed ID: 16495282
[TBL] [Abstract][Full Text] [Related]
34. Activity of glycylcyclines CL 329998 and CL 331002 against minocycline-resistant and other strains of methicillin-resistant Staphylococcus aureus.
Hamilton-Miller JM; Shah S
J Antimicrob Chemother; 1996 Jun; 37(6):1171-5. PubMed ID: 8836820
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell K
Antimicrob Agents Chemother; 2000 Oct; 44(10):2747-51. PubMed ID: 10991855
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of Bay Y3118 against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
[TBL] [Abstract][Full Text] [Related]
37. High rate of non-susceptibility to metronidazole and clindamycin in anaerobic isolates: Data from a clinical laboratory from Karachi, Pakistan.
Sheikh SO; Jabeen K; Qaiser S; Ahsan ST; Khan E; Zafar A
Anaerobe; 2015 Jun; 33():132-6. PubMed ID: 25800668
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes.
Werner H; Heizmann W; Luft G
Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of new investigational agents against Helicobacter pylori.
Osato MS; Reddy SG; Piergies AA; Bochenek WJ; Testa RT; Graham DY
Aliment Pharmacol Ther; 2001 Apr; 15(4):487-92. PubMed ID: 11284777
[TBL] [Abstract][Full Text] [Related]
40. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
Watt B; Naden M
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
